News und Analysen
EQS-News: M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31
EQS-News: M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
EQS-News: MEDICLIN AG: Annual General Meeting approves all proposed resolutions
EQS-News: MEDICLIN AG: Annual General Meeting approves all proposed resolutions
EQS-News: Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
EQS-News: Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
EQS-Adhoc: FamiCord AG acquires majority stake in Národní Centrum Pupečníkové Krve and Rodinná banka perinatálnych a mezenchymálnych buniek
EQS-Adhoc: FamiCord AG acquires majority stake in Národní Centrum Pupečníkové Krve and Rodinná banka perinatálnych a mezenchymálnych buniek
EQS-News: MPH Health Care AG publishes Annual Report 2024: Further increase in earnings and equity
EQS-News: MPH Health Care AG publishes Annual Report 2024: Further increase in earnings and equity
EQS-News: BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25
EQS-News: BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25
EQS-News: FamiCord AG starts 2025 financial year with accelerated growth and increases profitability at almost all earnings levels
EQS-News: FamiCord AG starts 2025 financial year with accelerated growth and increases profitability at almost all earnings levels
EQS-News: MeVis publishes figures for the first half of fiscal year 2024/2025
EQS-News: MeVis publishes figures for the first half of fiscal year 2024/2025
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
EQS-News: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
EQS-News: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
EQS-News: Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
EQS-News: Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
EQS-News: M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership
EQS-News: M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership
EQS-News: BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
EQS-News: BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
EQS-News: Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
EQS-News: Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: MEDICLIN increases group operating result in the first quarter of 2025
EQS-News: MEDICLIN increases group operating result in the first quarter of 2025
EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25
EQS-News: FamiCord AG continues growth course in 2024 after strong year-end business and stabilizes business development in home market Germany
EQS-News: FamiCord AG continues growth course in 2024 after strong year-end business and stabilizes business development in home market Germany
EQS-News: Equity (NAV) increases by almost EUR 27 million to EUR 277.9 million, corresponding to EUR 64.90 per share. EBIT increases by EUR 2.75 million to EUR 33.0 million. The equity ratio rises to 95.5%.
EQS-News: Equity (NAV) increases by almost EUR 27 million to EUR 277.9 million, corresponding to EUR 64.90 per share. EBIT increases by EUR 2.75 million to EUR 33.0 million. The equity ratio rises to 95.5%.